CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 8,087 Shares

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 8,087 shares of CeriBell stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $18.25, for a total transaction of $147,587.75. Following the transaction, the chief technology officer owned 166,912 shares in the company, valued at approximately $3,046,144. The trade was a 4.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Raymond Woo also recently made the following trade(s):

• On Monday, February 23rd, Raymond Woo sold 705 shares of CeriBell stock. The stock was sold at an average price of $19.79, for a total value of $13,951.95.
• On Friday, January 2nd, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $21.18, for a total value of $235,352.16.

CeriBell Stock Up 1.4%

CeriBell stock traded up $0.25 during mid-day trading on Wednesday, hitting $17.79. The company’s stock had a trading volume of 61,083 shares, compared to its average volume of 346,915. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $24.33. The company has a market cap of $669.62 million, a PE ratio of -12.10 and a beta of 1.12. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 9.35. The firm’s 50 day moving average is $20.98 and its 200 day moving average is $16.40.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $24.78 million during the quarter, compared to analyst estimates of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. On average, analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

CBLL has been the topic of several research analyst reports. TD Cowen restated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Canaccord Genuity Group boosted their target price on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. BTIG Research reaffirmed a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. Finally, JPMorgan Chase & Co. reduced their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Hedge Funds Weigh In On CeriBell

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp lifted its stake in shares of CeriBell by 1,945.9% in the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares during the last quarter. KCM Capital Inc bought a new position in CeriBell in the 4th quarter worth $21,930,000. Royce & Associates LP acquired a new position in CeriBell during the 4th quarter worth $11,695,000. Adage Capital Partners GP L.L.C. bought a new stake in CeriBell during the fourth quarter valued at about $10,965,000. Finally, CenterBook Partners LP grew its position in shares of CeriBell by 448.0% in the third quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after purchasing an additional 389,584 shares during the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.